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ABSTRACT 
The Qualified Presumption of Safety (QPS) approach, initially developed for the assessment of microorganisms 
referred to EFSA and added to the food chain is equally applicable to the assessment of botanicals or botanical 
preparations. Using the principles to establish the suitability of a botanical preparation for QPS status, it has been 
possible to develop a structured assessment scheme that provides a practical method for assessing botanicals and 
botanical preparations for which an adequate body of knowledge exists and therefore without the need for further 
testing. Reiterative applications of the assessment scheme to related botanicals or different botanical preparations 
obtained from the same plant variety can allow a QPS status to be derived for specific groupings. However, the 
particularity of botanicals that may be presented in a wide variety of forms or whose morphology and chemical 
composition may be markedly affected by geographical and environmental factors, makes the possibility to 
establish QPS status at high taxonomic levels quite limited. Still, the above-mentioned structured approach for 
the  assessment  of  botanicals  and  botanical  preparations  represents  a  considerable  advancement  in  the 
development  of  a  comprehensive,  systematic  and  transparent  methodology.  The  Scientific  Committee 
recommends its use as an extension of the 2009 EFSA guidance for the safety assessment of botanicals and 
botanical preparations intended to be used in food supplements.  
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SUMMARY 
The  European  Food  Safety  Authority  (EFSA)  asked  the  Scientific  Committee  to  consider  the 
applicability of the Qualified Presumption of Safety (QPS) approach for the safety assessment of 
botanicals / botanical preparations. 
The QPS approach was initially developed for the assessment of microorganisms referred to EFSA 
and added to the food chain; it requires four elements: i) the ability to establish the identity of the 
group of organisms considered, ii) the need for a sufficient body of knowledge to define its nature, iii) 
the consideration of possible pathogenicity and whether a qualification could be introduced to exclude 
pathogenic strains, and iv) information on the intended use. A basic tenet of the QPS approach as 
originally conceived was that suitability for the QPS approach should be established at the highest 
taxonomic level possible. 
The above-mentioned four elements are equally applicable to the QPS assessment of botanicals or 
botanical preparations. The particularity of botanicals that may be presented in a wide variety of forms 
or  whose  morphology  and  chemical  composition  may  be  markedly  affected  by  geographical  and 
environmental factors may introduce substantial compositional differences between preparations from 
the same plant species. As a result, the possibility to establish QPS status at high taxonomic levels will 
be quite limited. 
Using these principles, it has been possible to develop a structured assessment applicable to botanicals 
and  botanical  preparations  used  in  food  which  took  as  its  starting  point  the  existing  Guidance 
document  on  the  safety  assessment  of  botanical  supplements  that  also  introduces  the  concept  of 
presumption of safety in its first assessment level.  
An exercise with examples showed that it is possible to create a list of plants for which a presumption 
of safety could be established. Data were collected for the purpose of this testing exercise only and are 
not the result of a structured data search. As such, the outcome of these QPS assessments should not 
be  used  elsewhere  to  support  the  safety  of  the  botanicals  and  botanical  preparations.  For  some 
botanicals, it may be possible to list individual species or groups of species from the same genus as is 
done for microorganisms, with the implication that use of the raw material or any extract of that 
material is presumed safe (subject to any qualifications). However, in contrast to the QPS list for 
microorganisms, the number of compounds of concern and their potential for differential extraction 
would mean that for other species only specific extracts could be included. As with microorganisms, 
exclusion from a QPS list would not imply a botanical or botanical preparation is unsafe, but that a 
case-by case assessment is required. 
In addressing the mandate provided, the Committee also considered, within the overall context of the 
EFSA safety assessment strategy, the value of making the necessary pre-assessments and developing a 
list of botanicals and botanical preparations which could be presumed safe. This opinion shows that 
the pre-assessment of a very large number of botanicals and their preparations would be demanding of 
resources and time. Where use is likely to be restricted to sensory purposes, the QPS approach offers 
only limited advantages over the existing methodologies and may not be cost-effective in the short 
term. Relatively few botanical preparations have multiple uses, particularly when feed applications are 
not considered. Consequently there are only a limited number of occasions when the same material is 
subject to assessment under different regulations and by different panels. The  few occasions when this 
does occur could be handled by normal processes within EFSA and would not justify establishing a 
QPS approach. 
Finally, it should be underlined that the structured approach for the assessment of botanicals and 
botanical  preparations  described  in  Figure  1  represents  a  considerable  advancement  in  the 
development of a comprehensive, systematic and transparent methodology. The Scientific Committee 
recommends its use as an extension of the 2009 EFSA guidance for the safety assessment of botanicals 
and botanical preparations intended to be used in food supplements. Recommendation is made that QPS approach for the safety assessment of botanicals 
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EFSA keeps track of the safety evaluations of specific botanical preparations in conformity with the 
methodology described in the present paper, as a comparison of such individual assessments may lead, 
in the future, to the establishment/enlargement of a specific QPS status. QPS approach for the safety assessment of botanicals 
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BACKGROUND AS PROVIDED BY EFSA 
The evaluation  of the safety  and  efficacy  of  botanicals is currently  covered by  several  European 
regulations  depending  on  their  application  (see  Appendix  A).  The  existing  regulations  on  feed 
additives and on traditional medicinal products allow for an integrated assessment of botanicals and 
botanical preparations (looking both at safety and efficacy aspects). For food use, the responsibility for 
safety is left to the manufacturers and Member States‟ Competent Authorities, while EFSA has been 
charged with the evaluation of the scientific substantiation of claimed beneficial effects.  
Traditional use of botanicals and botanical preparations in a specific country has been the main basis 
for accepting the use of food supplements and/or traditional medicinal products and/or other products 
(e.g. teas and infusions).  
At present, EFSA is required to evaluate botanicals / botanical preparations in the following areas: 
  ANS: safety evaluation of botanicals / botanical preparations included in food supplements, 
safety evaluation of additives derived from botanical sources. 
  CEF:  safety  evaluation  of  botanicals  /  botanical  preparations  from  non-food  sources  for 
flavouring applications; 
  FEEDAP: evaluation of safety and efficacy of around 300 botanicals with feed applications; 
  NDA: evaluation of 1548 botanical claims on hold until the European Commission clarifies 
which approach to take;  
The novel food regulation currently under revision (see Appendix A) implies that EFSA should have 
the capacity to quickly review the safety of botanicals which are “novel” for the European market, but 
have a history of safe use in their country of origin, and eventually raise safety objections that would 
call for a full safety assessment of the botanical.  
A number of tools and guidance have already been developed by EFSA for assessing botanicals and 
botanical preparations (see section 2). However, a generic assessment system allowing for priority 
setting among the botanicals the Panels have to evaluate has not been established. Such a generic 
assessment system should be transparent, consistent across the EFSA Panels, take account of the 
whole body of knowledge on a particular botanical, including its history of safe use, in order to focus 
resources on botanicals or botanical preparations presenting greater risks or uncertainties. 
 
TERMS OF REFERENCE AS PROVIDED BY EFSA 
The  European  Food  Safety  Authority  requests  the  Scientific  Committee  to  develop  a  generic 
assessment system allowing for priority setting among the botanicals the Panels have to evaluate. The 
system  should  be  transparent,  ensuring  a  consistent  approach  across  the  EFSA  Panels,  and  take 
account of the whole body of knowledge on a particular botanical, including its history of safe use. 
The Scientific Committee is requested to perform this mandate in two steps: 
Develop a generic system for setting priorities among the botanicals to be assessed. For this purpose, 
the Scientific Committee is requested to consider:  
The guidance for the safety assessment of botanicals and botanical preparations intended for use as 
ingredients  in  food  supplements  (EFSA,  2009),  which  foresees  that  botanicals  or  botanical 
preparations for which an adequate body of knowledge exists could benefit from a “presumption of 
safety” without any need for further testing. QPS approach for the safety assessment of botanicals 
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The applicability for botanical species of a Qualified Presumption of Safety (QPS) approach, similar 
to that developed for the assessment of selected microorganisms referred to EFSA and added to the 
food chain (EFSA, 2007). 
The generic system will be tested with several examples taken from the Compendium of botanicals 
reported  to  contain  inherent  substances  of  possible  concern  for  human  health  (EFSA  Scientific 
Committee, 2012b). Should the botanical genus or species considered contain substance(s) of possible 
concern, the possibility to identify a dose under which such substance(s) could be concluded as being 
of no concern will be explored. 
If deemed feasible and appropriate, define subsequent steps to develop a list of botanicals that are 
suitable for QPS status. 
 
 QPS approach for the safety assessment of botanicals 
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ASSESSMENT 
1.  INTRODUCTION  
In 2007 EFSA formally introduced a novel system for the assessment of safety of microorganisms 
deliberately introduced into the food chain, based on a qualified presumption of safety (QPS) (EFSA, 
2007). This was done to avoid unnecessary duplication of efforts within EFSA and to aid the focussing 
of  activities  on  those  organisms  likely  to  present  the  greatest  risks.  All  potential  candidate 
microorganisms were initially assessed for their suitability for inclusion in the system, independent of 
any specific authorisation process. A number of species were identified for which no safety concerns 
were found and these formed the basis of the QPS list. All strains identified as belonging to the listed 
species  are  then  presumed  safe  without  any  further safety  assessment.  For  some  other  species, a 
proportion of strains were recognised to present a specific hazard such as the ability to elaborate a 
toxin. Provided that a proven method existed to identify the hazardous strains (the qualification) then 
the  species  was  also  included  in  the  QPS  list.  In  this  case  only  those  strains  which  meet  the 
qualification and are shown to be free of the recognised hazard are presumed safe. 
Four elements, referred to as pillars, were considered when establishing whether the QPS approach 
was  suitable for  a  defined  taxonomic  group  (e.g.  genus  or  species)  of  microorganisms.  First  and 
foremost was the ability to establish identity. Without an unambiguous definition of the taxonomic 
unit under consideration it would not have been possible to connect to the remaining pillars of the 
assessment. The second pillar asked whether there was a sufficient body of knowledge based on 
published data and/or experience to exclude the likelihood of a hazard or, if identified, to define its 
nature.  The  third  pillar  was  a  consideration  of  possible  pathogenicity  and  whether  with  existing 
knowledge a qualification could be introduced to be able to exclude pathogenic strains. The fourth and 
last pillar requires the assessment to take account of the intended use.  
The task of pre-screening of specific strains for use in the food chain was made easier by the relatively 
few  microbial  taxonomic  units  involved  and  by  the  increasing  availability  of  genomic  data  and 
bioinformatics analysis assisting in identifying potential hazards. This, coupled with a history of use, 
i.e.  significant  human  consumption,  ideally  over  a  period  of  several  generations  by  a  diverse 
population covering a wide range of genetic backgrounds and age groups, and the absence of clinical 
indications, allowed conclusions on the safety for defined taxonomic groups, with a high degree of 
certainty regardless of use. 
The QPS list of microorganisms is updated annually by the Panel on Biological Hazards. For strains 
belonging to taxonomic units excluded from the QPS approach, a case-by-case assessment is required. 
 
Botanicals and botanical preparations 
Recognising that concerns regarding the safety of botanical preparations used in food were widely 
raised in Member States, EFSA developed and published a guidance document that can be used for the 
safety assessment of botanicals and botanical preparations intended for use as ingredients in food 
supplements (EFSA, 2009). At the same time EFSA, in conjunction with Member States, began to 
develop  a  Compendium  of  Botanicals listing  those plants  reported  to contain  toxic  substances  or 
components that might otherwise be of concern (EFSA Scientific Committee, 2012b).  
The Guidance developed by EFSA describes a two tier approach in which the first level, described as 
Level A, is a safety assessment based on available knowledge. If the available data are considered 
inadequate to reach a sound conclusion on safety, Level B applies which foresees the generation of 
additional  (toxicological)  data.  At  Level  A  it  may  be  concluded  that  a  botanical  or  botanical 
preparation for which an adequate body of knowledge exists could benefit from a “presumption of 
safety”  without  any  need  for  further  testing.  The  knowledge  needed  to  reach  such  a  conclusion QPS approach for the safety assessment of botanicals 
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resembles  in  some  aspects  that  used  to  establish  the  suitability  of  microorganisms  for  the  QPS 
approach. Both require a clear definition of the material being considered (first pillar in QPS for 
microorganisms) and familiarity including evidence of a history of safe use and the absence of any 
reported  adverse  effects  (equivalent  to  second  pillar  in  the  QPS  approach  for  microorganisms). 
However,  it  differs  in  one  important  respect  from  the  approach  taken  with  microorganisms. 
Conclusions on the safety of strains of microorganism included in the QPS are made without any 
restrictions on use or level of exposure. This is not the case with Level A which carries the restriction 
that  “no  significant  increase  of intake  compared  to historical  levels  is  to  be  expected  due  to the 
intended levels of use in food supplements. This implies that not only use levels but also chemotypes 
of botanicals and the chemical compositions of the botanical preparations should be in line with those 
historically used. This approach can only be applied when intakes due to the intended levels of use are 
within the range of intake levels derived from the European Member States‟ average diets or from 
studies on specific subgroups. It is recognized that the acceptability of such an approach relies mainly 
on  the objective  of  not  significantly  increasing  exposures  beyond the levels linked  to the  “(safe) 
history of use”. 
 
Application of QPS to botanicals and botanical preparations 
Both the Guidance and the Compendium are tools intended to aid the assessment of botanicals and 
botanical preparations. They are not intended to produce a list of botanicals and botanical preparations 
that might be presumed safe. However, those botanical preparations which satisfy the criteria laid 
down in Level A of the EFSA guidance could form the basis for a list akin to that developed for 
microorganisms  thought  suitable  for  a  QPS  approach.  A  QPS  approach  applicable  to  selected 
botanicals  could  offer  advantages  for  much  the  same  reasons  as  led  to  its  development  for 
microorganisms  (e.g.  avoiding  repetitive  assessments,  ensuring  consistency  of  approach,  directing 
focus to the more hazardous items).  
The present opinion deals principally with botanicals and botanical preparations entering the food 
chain as food flavourings, food additives, as ingredients in food supplements, and as pesticides and 
biocides. A summary of the regulatory frameworks applicable to botanicals is provided in Appendix 
A. This opinion does not address the use of botanicals and botanical preparations in animal feed for 
two reasons. Firstly, whole plant material is considered a feed material and as such is excluded from 
any requirement for a safety assessment. Secondly, while plant extracts are considered feed additives 
and do require formal assessment, the considerable differences in absorption, distribution, metabolism 
and excretion found amongst livestock including fish makes it unlikely that a composite conclusion 
necessary for a QPS approach could be achieved.  
In  addressing  the  mandate  provided,  the  Committee  first  considered  the  criteria  to  establish  the 
suitability for a QPS approach to assess the safety of botanicals and how a structured judgement might 
be made. This took as its starting point the level A of the Guidance document for the safety assessment 
of botanicals, but where possible extended its scope beyond the constraint imposed by historical levels 
of  exposure.  A  number  of  practical  examples  were  then  selected  to  test  the  applicability  of  the 
proposed methodology. Finally, the costs and benefits of making the necessary pre-assessments and 
developing  a  list  of  botanicals  and  botanical  preparations  which  could  be  presumed  safe  were 
considered within the overall context of the EFSA safety assessment strategy.  QPS approach for the safety assessment of botanicals 
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2.  EFSA  GUIDANCE  DOCUMENTS  FOR  THE  SAFETY  ASSESSMENT  OF  BOTANICALS  AND 
BOTANICAL PREPARATIONS INTENDED FOR USE AS INGREDIENTS IN FOOD SUPPLEMENTS 
The Scientific Committee focussed its work on botanicals and botanical preparations, including food 
supplements; the proposed approach for safety assessment is however applicable to other uses of 
botanicals  and  botanical  preparations  in  the  food  and  feed  areas.  The  guidance  of  the  Scientific 
Committee for the safety assessment of botanicals comprises:  
  a list of technical, exposure and toxicological data needed to assess the safety of botanical 
ingredients.  
  a two-steps approach for safety assessment.  
The first level (level A) of the two-steps approach described in the SC Guidance (EFSA, 2009) makes 
use of the information on history of safe food use in Europe and the above-mentioned data directly 
available from the literature. Provided that no significant increase of intake compared to historical 
levels of intake of the botanical ingredient under consideration is expected due to the intended level of 
use in food supplements and whenever available data would  demonstrate that exposure to known 
levels of the botanical ingredient has occurred in large population groups for many years without 
reported adverse effects, a presumption of safety may be applied to the considered preparation without 
any  further  request  for  testing.  Botanicals  reported  to  contain  substances  of  concern  (see  EFSA 
Compendium of botanicals reported to contain naturally occurring substances of possible concern for 
human health when used in food supplements (EFSA Scientific Committee, 2012b) could also be 
granted presumption of safety provided that intake remains below an acceptable health-based guidance 
value.  
Exposure  to  the  substance(s)  of  concern  can  also  be  considered  in  relation  to  the  Threshold  of 
Toxicological Concern (TTC) values. The EFSA Scientific Committee evaluated in 2012 the TTC 
approach as a tool for providing scientific advice about possible human health risks from low level 
exposures and its applicability to EFSA‟s work (EFSA Scientific Committee, 2012c). The opinion of 
the Scientific Committee identified however a number of (categories of) substances for which the TTC 
approach should not be used:  
  High potency carcinogens (i.e. aflatoxin-like, azoxy- or N-nitroso-compounds, benzidines, 
hydrazines). 
  Inorganic substances 
  Metals and organometallics 
  Proteins 
  Steroids 
  Substances that are known or predicted to bioaccumulate 
  Nanomaterials 
  Radioactive substances 
  Mixtures of substances containing unknown chemical structures 
The EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS Panel), in its guidance 
document on the scientific data required to be submitted for food additive evaluations (EFSA ANS 
Panel,  2012)  refers  to  the  SC  guidance  for  the  safety  assessment  of  botanicals  and  botanicals 
preparations (EFSA, 2009) for the assessment of additives derived from botanical sources. The ANS 
guidance gives the possibility for botanical food additives derived from conventional food sources 
with a long history of food use to benefit from a “presumption of safety” under certain circumstances 
when  an  adequate  body  of  knowledge  exists.  The  Panel  took  note  of  the  requirement  in  the  SC 
guidance on botanicals that “no significant increase of intake compared to historical levels is to be 
expected  due  to  the  intended  levels  of  use”  and  further  clarified  that  the  definition  of  what  is 
considered a significant increase, compared to historical levels, should be judged on a case-by-case QPS approach for the safety assessment of botanicals 
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basis, as this implies that not only use levels but also chemotypes of botanicals and the chemical 
compositions of the botanical preparations should be in line with those historically used.  
In  cases  where  the  anticipated  intake  of  the  botanical  ingredient  is  significantly  higher  than  the 
estimated  historical  intake  level,  or  where  no  historical  intake  level  could  be  identified,  the  SC 
guidance on botanicals requires that additional exposure data are provided and assessed under the 
second level (level B) of the assessment. Where it was not possible to conclude on presumption of 
safety at the level A assessment because of lack of data on some toxicological aspects, additional 
toxicological studies should be carried out and assessed under level B as well. Both the SC and the 
ANS guidance documents describe the type of studies needed in relation to the different toxicological 
endpoints (EFSA, 2009; EFSA ANS Panel, 2012).  
For  compounds  that  are  genotoxic  and  carcinogenic,  the  Scientific  Committee  recommends  the 
Margin of Exposure (MOE) approach (EFSA, 2005); the Scientific Committee clarifies in its opinion 
that substances which are both genotoxic and carcinogenic should not be deliberately added to foods 
but  does  not  mention  specifically  how  to  address  naturally  occurring  genotoxic  and  carcinogenic 
substances in botanicals or botanical preparations that have a long tradition of food use. In a follow-up 
statement published in 2012, The Scientific Committee clarified that the recommendation to use the 
MOE approach holds true also for impurities, such as unavoidable contaminants, residuals and by-
products resulting from a production process (EFSA Scientific Committee, 2012a). In the case of 
impurities, breakdown and reaction products, metabolites, and low-level contaminants in food where 
an exposure assessment can be conducted, but on which there are few or no toxicological data, both 
the Scientific Committee and the ANS Panel suggested the use of the TTC approach (EFSA ANS 
Panel, 2012, EFSA Scientific Committee, 2012c). 
 
Determining the suitability of a botanical or a botanical preparation for inclusion in a QPS list 
It is recognised that there are significant differences in the assessment of botanicals compared to 
microorganisms which must be taken into account when assessing the suitability of a QPS approach to 
botanicals and botanical extracts. Relatively few microbial species are used by the food/feed industries 
compared  to  the  many  hundreds  of  botanical  species.  Similarly  microorganisms  are  fed  as  live 
organisms not subject to further treatment while botanicals may be presented in a wide variety of 
forms (e.g. different parts and extracts) introducing substantial compositional differences between 
preparations from the same botanical species.  
A basic tenet of the QPS approach as originally conceived was that suitability for the QPS approach 
should be established at the highest taxonomic level possible. For botanicals it is difficult to apply this 
principle.  Many  genera  of  plants  contain  hundreds  of  species/subspecies,  few  of  which  are  fully 
characterised and consequently any pre-assessment may well be limited to a single species or even an 
extract or a specific part of a plant. In addition, morphology and chemical composition of plants may 
be  markedly  affected  by  geographical  and  environmental  factors,  not  least  from  the  selection  of 
cultivars  appropriate  for  a  given  region.  All  of  these  factors  will  influence  the  possibilities  for 
grouping of botanicals and botanical preparations in a QPS approach and influence the decision on 
what materials can be included in the assessment. 
Figure  1  presents  a  flow  chart  with  a  possible  approach  for  the  assessment  of  botanicals  and/or 
botanical preparations, based on the data available, i.e. without requesting any testing. Given that the 
proposed approach is based on the data available without any further additional testing, it is basically 
in line with the so-called Level A assessment described in the SC guidance for the safety assessment 
of  botanicals  and  botanical  preparations  (EFSA,  2009)  and  allows  to  eventually  conclude  on 
presumption of safety. The diagram includes various steps and should be applied in an iterative way 
considering upon finalising the QPS evaluation for one preparation whether other preparations or even 
preparations of related botanical species can be included. The next section describes in further details 
the various steps of the proposed approach for the QPS assessment of botanicals and/or botanical 
preparations.  QPS approach for the safety assessment of botanicals 
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Figure 1:   Flow diagram of the proposed methodology for QPS assessment of botanicals and botanical preparations. QPS approach for the safety assessment of botanicals 
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Step 1: Defining the botanical species, part(s) of plant and preparation(s) of interest  
In a first step, it has to be defined what plant species and what plant part(s) and type of preparation(s) 
are  to  be  assessed.  Given  the  large  variation  in  composition  that  may  exist  between  different 
subspecies/varieties of a botanical species, between a botanical grown under different environmental 
conditions,  between  different  parts  of  the  same  botanical,  and  between  preparations  made  using 
different  manufacturing  processes,  -for  example  different  extraction  methods  leading  to  different 
substances being extracted-, it is important to carefully define at the very beginning the botanical 
species and (part)s of the plant and preparations evaluated. Guidance on how to do this can be found in 
the previous EFSA opinion defining guidance on the safety assessment of botanical and botanical 
preparations intended for use as ingredients in food supplements (EFSA, 2009).  
 
Step 2: Evaluating the compositional / toxicological / use data 
In  the  second  step,  one  should  review  the  available  data  on  the  composition  and  toxicity  of  the 
botanical  or  botanical  preparation  as  well  as  its  constituents.  Adequate  compositional,  use,  and 
toxicological data should be collected in line with what has been described before in the Guidance on 
safety assessment of botanicals and botanical preparations intended for use as ingredients in food 
supplements  (EFSA,  2009). The history  of  use  should  also  be considered  as  part  of  the  body  of 
knowledge in line with the level A evaluation described in this Guidance. This knowledge can be 
especially of importance if the evaluation according to the decision tree in Figure 1 would lead to 
acceptance of only unrealistically low exposure levels compared to historical use levels. This process 
of data collection should define all biologically active substances described in the literature that have 
been  identified  in  the  botanical  or  botanical  preparation,  also  including  their  actual  levels.  It  is 
essential to define the percentage of the material that has been characterised, and what percentage of 
the preparation evaluated remains unidentified. In this process of identifying substances of concern 
other  sources  of  data  suggesting  possible  adverse  effects  and  toxicity  linked  to  the  botanical  or 
botanical preparation under evaluation must be included. Information on substances of concern can 
relate to isolated substances but can also be derived from data on the extract itself. If available, data on 
matrix and combination effects may also be taken into account when defining substances of possible 
concern. 
Furthermore, the possibility of cross contamination from one part of the plant with compounds of 
concern to other parts of the same plant should also be considered. An example is the presence of 
morphine and codeine usually detected in Papaver somniferum L. (opium poppy) seed samples due to 
contamination with the latex or other parts of the plant (EFSA CONTAM Panel, 2011) 
If compositional / toxicological / use data are available these data are evaluated in the next step. 
 
Step 3: Evaluating the compositional / toxicological data 
Once the available and relevant compositional and toxicological data are defined this may result in 
five possible situations, reflected in Figure 1 (from right to left): 
The chemical characteristics of the botanical or botanical preparation are adequately defined and no 
adverse effects are reported. In such situations presumption of safety may be assigned without the 
need to introduce any qualifications, such as defining the exposure limit for which the QPS status 
holds.  
The  botanical  or  botanical  preparation  contains  substances  with  known  structures  but  unknown 
toxicity profiles. In such situations one may investigate whether based on validated in silico or read-QPS approach for the safety assessment of botanicals 
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across approaches adequate predictions can be generated without the need for further toxicological 
testing. If the in silico and/or read-across approaches do not give results suitable for subsequent risk 
assessment, the botanical or botanical preparation will require further toxicological testing and has to 
be excluded from the QPS approach until additional data have been provided. In case in silico or read-
across  methods  can  generate  information  on  the  substances  with  known  structures  but  unknown 
toxicity profiles, the botanical preparation may be granted QPS status without qualification, provided 
chemical characterisation was adequate and there were no reports on adverse effects. In the case where 
in silico and read-across methods identified possible toxicity, the substance becomes a “substance of 
concern” and the preparation shall then be evaluated for possible QPS status following the approach 
described in the next bullet point. The in silico predictive models are essentially based on structure-
activity  relationship  (SAR),  quantitative  structure-activity  relationship  (QSAR),  or  a  read-across 
between a group of analogous compounds that have structural and/or functional similarities to the 
untested compound. A wide range of methods and tools is already available for in silico toxicological 
profiling of a wide range of chemical substances, and can also be useful for compounds from botanical 
or other natural sources. Expert systems, on the other hand, can combine different in silico approaches 
to predict toxicity of a chemical substance from its structure. These may comprise decision-trees based 
on rules, structural alerts, and/or nested (Q)SARs. The (Q)SAR models are only reliable when they are 
tested rigorously for robustness and predictivity and their „applicability domain‟ is clearly defined. In 
regard to in silico estimation of toxicity of botanicals, the issue remains of how to assess such a 
mixture  where  more  than one  main  components  are  of  unknown  toxicological  significance.  Until 
recently  (Q)SAR  and  other  in  silico  methods  have  not  been  considered  useful  tools  for  such 
assessments, but work is ongoing to allow for the read-across assessment of mixtures. Finally it should 
be underlined that the use of the (Q)SAR models, expert systems, read-across tools, etc would need a 
clearly  identified  chemical  structure,  which  may  be  a  limiting  factor  for  the  application  of  the 
approach to botanicals and botanical preparations for which only limited analytical data are often 
available. 
The botanical or botanical preparation contains substance(s) of concern. When the substance is acting 
by a thresholded mode of action (MOA), the exposure resulting from the use of the botanical or 
botanical preparation must be evaluated against established health based guidance values, using a 
Margin of Safety (MOS) approach, or compared to available toxicity data or data on the history of safe 
use at specific exposure levels to define a safe level of intake. This safe level of intake can be taken as 
the basis to define QPS with a qualification defining the exposure limit for which the QPS status 
holds. If for the substance(s) of concern with a thresholded MOA, no health based guidance values or 
toxicity data enabling definition of a safe level of intake are available, one may apply the TTC concept 
(EFSA Scientific Committee, 2012c) to define an exposure qualification to be linked to the QPS 
status. Application of the TTC approach requires that the chemical structure of the substance(s) with 
unknown toxicity profile is defined. It is noted that, with the exception of flavour use, application of 
the TTC approach may often result in exposure qualifications for the QPS status that are far below the 
proposed uses and use levels of the botanicals or botanical preparation of interest finally resulting in 
excluding the relevant botanicals or botanical preparations from the QPS approach. If a safe level of 
intake for substance(s) of concern cannot be established, the botanical or botanical preparation cannot 
be assigned a QPS status. This is the case for substance(s) acting by a non-thresholded MOA, e.g. 
genotoxic  and  carcinogenic  substances.  The  Margin  of  Exposure  (MOE)  approach  (EFSA,  2005; 
EFSA Scientific Committee, 2012a) may be applied to define their level of concern but, given the 
recommendation of the Scientific Committee to not introduce in the food chain substances that are 
known to be genotoxic and carcinogenic (EFSA, 2005), these substances will be excluded from the 
QPS approach and therefore subject to a case-by-case assessment. 
The botanical or botanical preparation has been linked to adverse effects but compounds of concern 
are not identified. In this situation one may base the QPS decision on data available on the history of 
safe use at traditional exposure levels, provided that the adverse effects reported occurred at non-
traditional levels of use. If such data are not available, the botanical or botanical preparation should be 
excluded from the QPS approach. If data on the history of safe use at defined traditional exposure QPS approach for the safety assessment of botanicals 
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levels are available, these traditional exposure levels can form the basis to define a QPS status with 
qualifications. 
The final possible outcome may be that the botanical or botanical preparation contains a fraction of 
uncharacterised  substances.  This  may  often  be  the  case  since  full  chemical  characterisation  of  a 
botanical or botanical preparation may often not be available. In such situations one may also base the 
QPS decision on the available data on history of safe use at traditional exposure levels. If such data are 
not available the botanical or botanical preparation should be excluded from the QPS approach. If data 
on the history of safe use at defined traditional exposure levels are available these traditional exposure 
levels can form the basis to define a QPS status with qualifications. 
 
Products commonly eaten are presumed safe unless a significant risk has been identified. Absence of 
evidence of toxicity, however, is not necessarily evidence of absence of toxicity under the proposed 
conditions of usage (e.g. long-term use of herbal preparations). Therefore, when considering history of 
use and accumulating the body of knowledge describing the safety profile of a botanical preparation, a 
number  of  important  factors  should  be  considered  where  available:  the  period  over  which  the 
traditional preparation has been consumed, the way it has been prepared and used and at what intake 
levels, known limitations and restrictions for sensitive  populations, its composition, the results of 
animal studies, observations from human exposure and clinical reports (Constable et al. 2007).  
 
Step 4: Repeating the steps in an iterative process  
When  positive  conclusions  on  safety  have  been  reached,  either  with  qualifications  or  not,  after 
evaluating a specific botanical preparation, it may be relevant to repeat the process in an iterative way 
to other species / plant parts/ preparations. This step 4 should therefore include a consideration about 
whether  there  are  similar  preparations  from  other  subspecies/varieties/  species  for  which  the 
assessment could be relevant and if the safety evaluation could be extended to other preparations from 
other species/varieties, thus extending the number of botanical preparations for which the QPS status 
would hold. Considering which other botanical species/varieties and/or preparations could be covered 
by the specific safety evaluation can best be done starting from the chemical compositions. In fact, if 
the chemical compositions obtained from different species/varieties/plant parts or preparations are 
similar it would be reasonable to extend the safety evaluation obtained initially. This might be possible 
even  if  some  quantitative  differences  would  be  detected  among  the  chemical  compositions.  In 
addition, the described safety assessment procedure could be applied in an iterative manner, starting 
with  evaluation  of  one  botanical  and/or  botanical  preparation  and  subsequently  considering  the 
feasibility of expanding the conclusion(s) obtained to other species/varieties or botanical preparations. 
The grouping should preferably include plants relevant for food consumption and with a history of 
safe use. It is also important that the botanical species and preparations evaluated are chosen as broad 
as possible, although it is acknowledged that evaluation at the species level may often be hampered by 
the wide variability between related varieties within a species. In some cases QPS may be granted for 
a single preparation and no extension or iteration is possible hampering the suitability of the QPS 
approach at higher taxonomic levels. 
 
3.  TESTING THE SUITABILITY OF THE QPS APPROACH FOR BOTANICALS 
The present section aims at testing the proposed approach for the QPS assessment of botanicals and 
botanical preparations with selected case studies. Data were collected for the purpose of this testing 
exercise only and are not the result of a structured data search. The outcome of this assessment should 
not be used elsewhere to support the safety of the botanicals and botanical preparations. Further details 
on the data considered and how the flow diagram (Figure 1) was used for the QPS assessment of the 
selected case studies can be found in Appendix B.  QPS approach for the safety assessment of botanicals 
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There are species and genera for which compositional data exist but for which the Compendium and 
other sources do not identify substances of concern. One example is the fruit (hips) and petals of Rosa 
canina and related species. There is a long history of human consumption and more recently hips in 
concentrated form have been used in food supplements with a variety of claimed benefits, not all 
related to the recognised high concentration of vitamin C. Since a search revealed no reported adverse 
effects, apart from digestive tract and mouth irritation resulting from the ingestion of the hair-like 
layer under the flesh of the hips, the structured assessment in Figure 1 would lead to the outcome that 
R. canina fruit and petal could be included in a QPS list without qualifications. Repeating the process 
for other Rosa species would add to the list.  
Citrus also represents a genus for which extensive data on the composition of the fruit, peel, and 
essential  oils  derived  from  them  can  be  found  for  some  species.  However,  unlike  Rosa  spp.  the 
Compendium and the open literature identify the presence of linear furocoumarins with recognised 
phototoxic effects as compounds of concern in essential oils of many Citrus spp. Because of the use of 
such compounds in the oral treatment of skin diseases, their toxicokinetics are known and long and 
short term toxicity studies exist. From Figure 1 it is probable that sufficient toxicity data exist which 
would allow many Citrus spp to be included in a QPS list with a qualification relating to the linear 
furocoumarin content. However for a few Citrus spp., notably Citrus aurantium, a further compound 
of concern has been identified; animal experimental studies and human data have shown that Citrus 
aurantium  extracts  can  induce  cardiovascular  effects,  ascribed  to  the  presence  of  (-)-synephrine. 
Following Figure 1, (-)-synephrine is a thresholded substance for which no health-based guidance 
value was set. Since the existing toxicity data are insufficient to derive such a value, use of extracts of 
Citrus  aurantium  in  food supplements  would have  to  be  restricted  to levels where  no significant 
increase of (-)-synephrine exposure compared to historical intake levels with traditional foods is to be 
expected. Thus Citrus exemplifies a genus for which different conclusions with regard to a QPS 
approach would be reached for different species. 
Rosmarinus officinalis was selected because it represents a case where, although only a single species 
is generally used, many different preparations and extracts are used each with substantially different 
compositions. Unusually, non-aqueous extracts of rosemary leaves have already been assessed for 
safety by EFSA. This resulted in a QPS-like conclusion that non-aqueous extracts were safe for use in 
food provided a qualification that the carnosic acid plus carnosol content remained within specified 
limits  was  observed.  Although  the  Compendium  identifies  only  monoterpenes  as  compounds  of 
concern,  which  are  poorly  soluble  in  water,  aqueous  extracts  contain  very  high  concentration  of 
rosmarinic acid. The very limited available toxicity data for rosmarinic acid do not suggest a hazard 
but are insufficient to derive a threshold value. A QSAR approach may solve this issue and could 
allow a QPS listing without qualification. The essential oil of Rosemary has a high monoterpene 
content, notably camphor. The traditional use of rosemary  for abortion, coupled with preliminary 
evidence showing embryotoxic effects of the oil is cause for concern. Additionally, the oil provokes 
genotoxic  and  mutagenic  effects  when  administered  orally.  Consequently  the  essential  oil  is  not 
suitable for food use. Thus assessment of rosemary and its various extracts show that a composite 
conclusion on the species is not possible and that any QPS listing could apply only to specific extracts.  
Foeniculum  vulgare  (fennel)  and  Ocimum  tenuiflorum  (holy  basil)  present  similar  issues  as  both 
contain the genotoxic and carcinogenic agent estragole. Given the recommendation of the Scientific 
Committee  to  not  introduce  in  the  food  chain  substances  that  are  known  to  be  genotoxic  and 
carcinogenic (EFSA, 2005), Foeniculum vulgare and Ocimum tenuiflorum are excluded from the QPS 
approach. For risk management purposes, it may be of interest to assess preparations of these species 
on a case-by-case basis, using the carcinogenicity data for estragole from which a BMDL10 could be 
derived  and  for  which  it  is  therefore  possible  to  apply  the  MOE  approach.  The  fact  that  some 
preparations e.g. essential oils of Foeniculum vulgare and Ocimum tenuiflorum species will show 
higher levels of estragole than the levels extracted into (traditional) water based preparations should 
then be taken into account. For preparations other than the essential oil of Ocimum tenuiflorum, there 
is  an  additional  concern  related  to  reproductive  effects.  Since  the  chemical(s)  of  concern  for  the QPS approach for the safety assessment of botanicals 
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reproductive effects have not been identified and as the compositional data are limited, this is an 
additional argument to exclude extracts of O. tenuiflorum from QPS listing. 
Young leaves and leaf buds of Camellia sinensis are used unfermented and dried to produce traditional 
“green tea” as the basis for traditional aqueous green tea infusions and for the manufacturing of dried 
green  tea  extracts  for  food  supplement  use.  Although  there  are  no  significant  health  concerns 
associated with traditional consumption of green tea infusions, in recent years an association was seen 
between the intake of larger amounts of dried green tea extracts via food supplements to support 
weight-loss  and  the  occurrence  of  liver  damage.  One  component  of  green  tea  extracts,  (-)-
epigallocatechin-3-gallate (EGCG), the major catechin present, is associated with liver toxicity seen in 
animals and humans. EGCG is a thresholded substance with sufficient toxicity data to establish a 
health-based guidance value. Consequently dried green tea extracts from Camellia sinensis, following 
the scheme outlined in Figure 1 could be included in a QPS list with a qualification to protect against 
exposure to EGCG greater than the guidance value. 
 
The exercise above shows that it would be possible to create a list of plants for which a presumption of 
safety could be established. For some botanicals, it may be possible to list individual species or groups 
of species from the same genus as is done for microorganisms, with the implication that use of the raw 
material or any extract of that material is presumed safe (subject to any qualification). However, in 
contrast to the QPS list for microorganisms, the number of compounds of concern and their potential 
for differential extraction would mean that only specific extracts could be included. 
 
4.  VALUE FOR EFSA 
It has to be acknowledged that the pre-assessment of a very large number of botanicals and their 
preparations would be demanding of resources and time. Where use is likely to be restricted to sensory 
purposes  the  QPS  approach,  while  possible,  offers  only  limited  advantages  over  the  existing 
methodologies.  Relatively  few  botanical  preparations  have  multiple  uses,  particularly  if  feed 
applications are not considered. Consequently there are only a limited number of occasions when the 
same material is subject to assessment under different regulations and by different panels. Such few 
cases could be handled by normal processes within EFSA.  
One of the major benefits of the QPS approach applied to microorganisms is that the presumption of 
safety could be applied to strains falling within a defined taxonomic unit regardless of intended use. A 
parallel situation for botanicals would be more rarely encountered and the scope of application for 
those materials listed is likely to be more restrictive. Inevitably this reduces the value of the QPS 
approach to safety assessment, as some applications may be covered by the pre-assessment and others 
not. 
 
CONCLUSIONS AND RECOMMENDATIONS  
CONCLUSIONS 
The principles used to establish the suitability of a microbial group for inclusion in a QPS list of 
microorganisms can be applied in a similar manner to botanicals and botanical preparations. However, 
the  particularity  of  botanicals,  which  may  be  presented  in  a  wide  variety  of  forms  and  whose 
morphology and chemical composition may be markedly affected by geographical and environmental 
factors, makes the possibility of establishing QPS status at high taxonomic levels quite limited. QPS approach for the safety assessment of botanicals 
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Using the above-mentioned principles, it has been possible to develop a structured assessment scheme 
(see Figure 1)  applicable to botanicals and botanical preparations used in food which took as its 
starting  point  the  existing  EFSA  Guidance  document  on  the  safety  assessment  of  botanical 
supplements. 
Reiterative applications of the structured safety assessment scheme to related botanicals or different 
botanical preparations obtained from the same plant variety can allow a Qualified Presumption of 
Safety status to be derived for specific botanical groupings.  
When granting QPS status on the basis of history of use in the absence of reported adverse effect, it 
should be kept in mind that absence of evidence for adverse effect can not be taken as an evidence for 
the  absence  of  adverse  effect(s).  The  suitability  for  QPS  status  of  e.g.  preparations  containing 
substances that show a pharmacological effect at doses close to the levels of exposure resulting from 
the traditional use should be carefully considered, as there is a biological plausibility for an adverse 
health effect, although it has not been picked up by historical data. 
The exercise with examples carried out in the present opinion showed that it is possible to identify 
some plant species suitable for inclusion in a QPS list as is done for microorganisms. However, for 
other  plants,  because  of  the  number  of  compounds  of  concern  and  their  potential for  differential 
extraction, only specific extracts were considered suitable for inclusion.  
As  with  microorganisms,  exclusion  from  a  QPS  list  would  not  imply  a  botanical  or  botanical 
preparation is unsafe, but that a case-by case assessment of safety is required. 
The use of botanicals and botanical preparations in animal feed is excluded from consideration at this 
stage.  The  lack  of  category-specific  data  and  the  potential  differences  in  pharmacokinetics  found 
amongst livestock including fish makes it unlikely that a composite conclusion necessary for a QPS 
approach could be achieved.  
Relatively few botanical preparations have multiple uses, particularly when feed applications are not 
considered. Consequently there are only a limited number of occasions when the same material is 
subject to assessment under different regulations and by different panels. Such occasional duplications 
would not justify establishing a QPS list, as ensuring a uniformity of approach (and outcome) could be 
handled by existing processes within EFSA.  
The pre-assessment of even a selected number of botanicals and their preparations would be very 
demanding of resources and time. Where use is likely to be restricted to sensory purposes the QPS 
approach, while possible, offers only limited advantages over the existing procedure and may not be 
cost-effective in the short term. 
 
RECOMMENDATIONS 
The structured safety assessment scheme provides a practical method of implementing the Level A of 
the 2009 EFSA Guidance on the safety assessment of botanicals and botanical preparations intended 
for use as ingredients in food supplements. Since the scheme is not constrained by historical levels of 
exposure,  it  also  has  potential  application  for  the  safety  assessment  of  botanicals  and  botanical 
preparations in general. The Scientific Committee recommends that all panels dealing with botanicals 
are made aware of and encouraged to use the scheme.  
The Scientific Committee also recommends that a reference list of botanicals that have been subject to 
a safety assessment within EFSA should be maintained. This could be of immediate value to those 
assessing the same or similar material for a different end use. It could also allow, in the longer term 
and as the number of botanicals assessed increases, a QPS list to be produced by default without the 
need for extensive pre-assessments.  QPS approach for the safety assessment of botanicals 
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APPENDICES 
Appendix A.   Regulatory frameworks applicable to botanicals 
If a QPS approach is to be adopted then it must be able to co-exist with requirements established by 
existing regulatory frameworks:  
  Directive  2002/46/EC  sets  out  labelling  requirements  and  requires  that  EU-wide 
maximum  and  minimum  levels  are  set  for  each  vitamin  and  mineral  added  to 
supplements. The aim is to harmonise the legislation and to ensure that these products 
are safe and appropriately labelled so that consumers can make informed choices. 
Annex I lists the vitamins and minerals which may be used in the manufacture of food 
supplements.  Annex  II  of  Directive  2002/46/EC  is  a  list  of  permitted  vitamin  or 
mineral  substances  that  may  be  added  for  specific  nutritional  purposes  in  food 
supplements. It also allows the use for the same purpose of “other substances” with a 
nutritional or physiological effect, but definitions of such effects are not elaborated in 
the Directive. These two annexes have been replaced by the ones from Regulation 
(EC) N° 1170/2009 that takes account of new vitamin and mineral forms evaluated by 
EFSA and comments received from interested parties.  
  Regulation (EC) N° 1925/2006 on the voluntary addition of vitamins and minerals 
and certain other substances to food (fortified food). Article 8 of Regulation, focused 
on so called “other substances”, foresees a specific procedure in order to prohibit, 
restrict or place under scrutiny a substance other than vitamins or minerals that is 
added to foods under conditions that would result in the ingestion of amounts of this 
substance greatly exceeding those reasonably expected to be ingested under normal 
conditions  of  consumption  of  a  balanced  and  varied  diet  and/or  would  otherwise 
represent a potential risk to consumers. Member States can submit a request to the 
European  Commission,  providing  scientific  evidence  allowing  the  Commission  to 
classify a particular product in Annex III of the Regulation, in either:  
  Part A, when a harmful effect has been identified, and the addition of the products 
to food shall be prohibited, 
  Part B, when a harmful effect has been identified, and the addition of the products 
to food shall be allowed only under specific conditions, 
  Part C, if the possibility of harmful effects on health is identified but scientific 
uncertainty persists, and the substance shall be under Community scrutiny. 
Many supplements are marketed for supposed health benefits and there may be overlap with 
herbal medicinal products which are regulated in a manner distinct from that used for most 
food/feed products or ingredients. 
  Directive  2004/24/EC  on  “traditional  herbal  medicinal  products”  provides  for 
definitions of (i) traditional herbal medicinal products, (ii) herbal medicinal products, 
(iii)  herbal  preparations  and  (iv)  herbal  substances.  The  directive  introduces  three 
categories of products: 1) a product can be classified under traditional medicinal use 
provisions  („traditional  use‟)  accepted  on  the  basis  of  sufficient  safety  data  and 
plausible  efficacy  (at  least  30  years  of  use  including  at  least  15  years  within  the 
Community),  2)  a  product  can  be  classified  under  well-established  medicinal  use 
provisions („well-established use‟). This is demonstrated with sufficient safety and QPS approach for the safety assessment of botanicals 
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efficacy  data,  and  3)  a  product  can  be  authorised  after  evaluation  of  a  marketing 
authorisation application consisting of only product-specific safety and efficacy data 
(„full dossier‟).  
 
  Regulation (EC) N° 1924/2006 on nutrition and health claims made on food sets out 
the responsibility for EFSA to evaluate whether nutrition and health claims for foods 
are supported by sound science and, by doing so, to define the scientific requirements 
for the substantiation of claims. This regulation does not foresee an assessment of the 
safety of the product carrying the claim. Most of the claims submitted to the NDA 
Panel did not fulfil the criteria for scientific substantiation; their evaluation has been 
put on hold until the European Commission proposes an alternative solution. 
 
  Regulation (EC) N° 258/97 on novel foods is under a review process. It foresees a 
notification procedure to be introduced for foods which have not been traditionally 
sold  in  the EU but  which have a safe history  of  safe use in  third countries.  “For 
traditional food from third countries, a safety assessment and management based on 
history of safe food use in the country of origin shall be introduced. If the history of 
safe food use in the country of origin has been demonstrated, and the Member States 
and EFSA do not present reasoned safety objections, based on scientific evidence, the 
food could be placed on the market by means of a notification of the food business 
operator intending to market the food” 
 
  Regulation (EC) N° 1831/2003 provides a Community procedure for authorising the 
handling and marketing and use of feed additives and to lay down rules for the post-
authorisation monitoring and labelling of feed additives and their premixtures. EFSA 
has a key role in providing independent scientific advice to support the authorisation 
process for feed additives, evaluating both safety and efficacy.  
 
  Regulation (EC) N° 2232/96 sets out the main rules on the use of flavourings in foods 
in the EU. Based on this legislation a procedure was launched to establish an EU 
positive list of flavourings which will govern the flavourings that may be added to 
foods.  This  Regulation  was  amended  by  Regulation  (EC)  N°  1331/2008  that 
introduced a common approval procedure for additives, enzymes and flavourings used 
in  food,  based  on  scientific  opinions  from  EFSA,  and  Regulation  N°  1334/2008 
establishing an EU list of authorised flavouring substances. Data required for the risk 
assessment of flavourings other than chemically defined flavouring substances (e.g. 
botanicals / botanical preparations from non-food sources) are outlined in the EFSA 
guidance document (EFSA CEF Panel, 2010). QPS approach for the safety assessment of botanicals 
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Appendix B.   Case studies for testing the proposed approach for QPS assessment 
The following case studies are presented for the purpose to illustrate the applicability of the QPS 
approach to botanicals and botanical preparations. Data were collected for the purpose of this testing 
exercise only and are not the result of a structured data search. As such, the outcome of these QPS 
assessments  should  not  be  used  elsewhere  to  support  the  safety  of  the  botanicals  and  botanical 
preparations. 
 
B.1  Rosa canina  
Species, plant parts and preparations used  
Rosa canina L.; fruit, excluding the seed. 
 
Composition  
  pectin 
  sugars (sorbitol)  
  fatty acids 
  polyphenols (tannins) : proanthocyanidols and flavonoids  
  vitamin C (ascorbic acid): 0,5 to 1,7 %, beta-carotene, vitamin B1, vitamin B2, 
vitamin B3 and vitamin K  
  alpha-tocopherol,  
  other organic acids: citric, malic. 
  Minerals (Ca, Fe, K, Mn, Na, P, and Zn) 
 
Toxicity 
No  toxicity  reported.  No  reported  adverse  effect,  apart  from  digestive  tract  and  mouth  irritation 
resulting from the ingestion of the hair-like layer under the flesh of the hips 
 
Use 
The fruit can be eaten as such (after having removed the hairs); or in various types of preparation such 
as dried, in infusion, soups, macerated in beer, wine, or in jam. 
 
Result of evaluation 
Adequate compositional, toxicological and use data available. No reported adverse effect.  
Proposal to grant QPS without qualification for the fruit (excluding the seed) of Rosa canina.  
 
Iteration process: 
Chemical composition of the fruits of Rosa spp. appears to be rather stable (Ercisli, 2007). 
Fruits of the following species can be safely consumed when used appropriately: Rosa alba, Rosa 
centifolia, Rosa damascena (American Herbal Products Association, 1997). 
Flower petal use of Rosa rugosa is also categorised in class 1 of the Botanical Safety Handbook  
Rose (hips and petals) have no known specific safety issues 
 
Conclusion: Adequate compositional, adequate toxicity data (mostly based on history of safe use – 
absence of reported adverse effects) adequate use data available;  QPS approach for the safety assessment of botanicals 
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It is therefore proposed to extend QPS status without qualification to the following species for fruit 
and  petal:  Rosa  alba  L.,  Rosa  centifolia  L.,  Rosa  canina  L.,  Rosa  damascena  L.,  Rosa  dumalis 
Bechst., Rosa pisiformis Sosn., Rosa pulverulenta M. Bieb., and Rosa villosa L. 
 
B.2  Rosmarinus officinalis  
Species, plant parts and preparations used  
Rosmarinus officinalis L. Most scientific authorities recognise only the single species. Rosemary is 
available as various aqueous and non-aqueous preparations derived from the flowering dried twig tips, 
dried leaves, fresh leaves, the fresh aerial parts collected during flowering and the flowering branches. 
The essential oil of rosemary is distilled from the flowering tops or from stems and leaves of the plant 
taken before flowering.  
 
Composition  
Whole plant. Sufficient is known about the chemical composition of the aerial parts to recognise that 
the  plant  and  its  extracts  contain  substances  of  concern.  The  whole  plant  contains  a  range  of 
flavonoids  including  diosmetin,  diosmin,  genkwanin  and  derivatives,  luteolin  and  derivatives, 
hispidulin, neptin, nepitrin and apigenin). Other characteristic constituents are simple phenolic acids, 
phenolic diterpenes (carnosol, carnosolic acid, rosmanol, isorosmanol, epirosmanol, rosmaridiphenol, 
rosmariquinone), triterpenoids such as oleanolic and ursolic acids, α- and β-amyrin, and rofficerone 
and various hydroxycinnamic acid derivatives, e.g. rosmarinic acid. 
Extracts. Characteristic components of the essential oil are: 1,8-cineole, α-pinene, camphor, bornyl 
acetate, borneol, camphene and α-terpineol. Limonene, β-pinene, β-caryophyllene and myrcene are 
also  present.  Some  sources  indicate  p-cymene  and  linalool  as  important  constituents.  Solvent 
extraction generates products which differ significantly in comparison with the oil obtained through 
steam distillation. Notably the di- and tri-terpenes and triterprenic acids are selectively extracted while 
the volatiles typical of the essential oil are present only in low amounts.  
 
Toxicity 
Non-aqueous solvent extracts. The potential toxicity of non-aqueous extracts has been assessed by 
EFSA (2008). Five representative extracts were studied (acetone, ethanol alone or in combination with 
hexane and supercritical carbon dioxide). Extracts were non-genotoxic in a number of bacterial and 
mammalian test systems. Data from acute mouse toxicity studies (2), 14-day range finding studies in 
rats (2) and chronic oral toxicity studies in rats (6,) were examined. NOAEL values in the range 180 – 
400 mg extract/kg BW per day were identified from the 90-day studies equivalent to 20 – 60 mg/ kg 
BW per day carnosic acid plus carnosol. A comparison of the estimated potential exposure of adults 
and children to Rosemary extracts compared to the NOAEL values indicate margins of 200 – 600 (95
th 
percentile for adults) and 100 – 300 (95
th percentile, pre-school children). The ANS Panel concluded 
that  the  use  of  non-aqueous  solvent  extracts  of  Rosemary  could  be  safe  in  food  and  proposed 
maximum  use  levels.  These  have  now  been  established  in  legislation  (Commission  Directives 
2010/67/EU and 2010/69/EU). 
Aqueous extracts. Aqueous extraction favours the solubilisation of rosmarinic acid which can reach 
10% w/w of extracts. No oral toxicity studies made with aqueous extracts of Rosemary appear to have 
been  reported  other  than  a  (very)  preliminary  examination  of  effects  on  the  male  rat  when 
administered over five days at a dose level of 291.2 mg and 582.4 mg/kg of body weight. Rosemary 
extract at the lower dose did not affect body or organ weights, sperm production or food intake. At the QPS approach for the safety assessment of botanicals 
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higher dose there was a significant increase in seminal vesicle weight. These data are insufficient to 
derive a safe level of intake. 
Rosmarinic acid itself exhibits low toxicity (LD50 in mice is 561 mg/kg for intravenous administration) 
and is not mutagenic. It is well absorbed from the gastrointestinal tract and through the skin. However 
there are no health-based guidance values for rosmarinic acid and insufficient toxicity data from which 
a safe dose could be derived. 
Essential oil. Rosemary essential oil is contra-indicated for oral use. It is toxic even in fairly low 
doses, and a maximum safe dose has not been identified. Ingestion can result in stomach and intestinal 
irritation and kidney damage. Toxicity can be ascribed in part to camphor (and its metabolite borneol) 
and to the monoterpene ketones (limonene. α and β-pinene), which are convulsants, and have caused 
seizures in large doses. Rosemary is also an abortifacient based on its traditional use for abortion, as 
well as preliminary evidence showing embryotoxic effects. The oil provokes genotoxic and mutagenic 
effects when administered orally  based on the results of a comet micronucleus assay  and a bone 
marrow chromosome aberration test. Consequently use of the essential oil should be restricted to 
topical application and is not suitable for food use.  
 
Use 
Rosemary finds common use in food as a culinary herb, in beverages, and its extracts as food flavours, 
preservatives and antioxidants.   
 
Result of evaluation 
Aqueous extract: Composition well documented but, at present, there are insufficient data from which 
to derive a maximum safe intake. Based on the major component (rosmarinic acid), QPS qualification 
would have to be set based on the TTC approach. 
Non-aqueous extract: QPS with a qualification would ensure compliance with  set in Commission 
Directives. 
Essential oil: Oral use contra-indicated and so should be excluded from the QPS approach. 
 
Iteration process: 
No iteration is required for the non-aqueous extracts as adequate toxicology based on a representative 
range of extracts is available on which to base an assessment.  
Sufficient  compositional  data  for  the  aqueous  extracts  are  available  and  can  be  used  to  identify 
components  of  potential  concern  making  an  iterative  approach  possible.  However,  other  than 
rosmarinic acid, little data are available for the identification of safe intake levels and consequently the 
assessment of individual components is likely to default to the TTC approach.  Existing evidence 
would suggest that consumption of the essential oil is not desirable.  
 
B.3  Citrus aurantium  
Species, plant parts and preparations used  
Citrus x aurantium ssp. amara (Link) Engl. (synonym: Citrus aurantium L.)  
Dried hydro-alcoholic extracts of dried immature fruits and dried peel of the immature and mature 
fruit of Citrus x aurantium ssp. amara are available for food supplement use (Appendix A of the 
reference EFSA ESCO, 2009).  QPS approach for the safety assessment of botanicals 
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Composition 
Bitter orange peel 
An important constituent of the bitter orange peel is the essential oil. The pharmaceutically used bitter 
orange peel (Aurantii amari epicarpium et mesocarpium) being the dried epicarp and mesocarp of the 
ripe fruit of Citrus x aurantium ssp. amara partly freed from the white spongy tissue of the mesocarp 
and endocarp (Ph. Eur. 7, 2011) is said to contain 1.0-2.5 % essential oil (Aurantii amari aetheroleum, 
Oleum Aurantii corticis, Oleum Aurantii amari). The main component of the essential oil is limonene 
(up  to  90  %).  Several  other  monoterpenes  are  present  (citral,  linalool,  linalyl-,  neryl-,  geranyl-, 
citronellyl-acetate). Aliphatic aldehydes and methyl-anthranilate determine the fragrance of the oil. 
Coumarins and furocoumarins are also found in the non volatile part of the essential oil. Meranzin, 
isomeranzin, epoxybergamottin and bergapten are the major coumarin- and furocoumarin derivatives 
found in the essential oil of bitter orange peel (Ph. Eur. Comment., 2012). Reported concentrations in 
bitter orange oil are 0.31 - 1.2% for meranzin, 0.15 – 0.22% for isomeranzin, 0.18  – 0.33% for 
epoxybergamottin and 0.05 - 0.1% for bergapten (Hager, 2006). 
The  bitter  substances  of  the  bitter  orange  peel  are  flavonoids  (flavanones  glycosylated  with 
neohesperidose, e.g. naringin, neohesperidin, neoeriocitrin) and tetranortriterpenes (limonoids) (Hager, 
2006).  
(-)-Synephrine ((-)-p-methylaminoethanolphenol) and octopamine are the most frequently mentioned 
biogenic amines found in bitter orange peel, however, there is no evidence that octopamine or other 
phenethylamine alkaloids are present in bitter orange peel in any appreciable levels. Analyses of the 
dried peels of fruits and of dried fruits have shown a variation of the levels of (–)-synephrine from 0.1 
to 2.0 %. (-)-synephrine and related alkaloids appear to be present in slightly higher quantities in the 
unripe  fruit  than  in  the  ripe  fruit.  (-)-Synephrine  is  a  sympathomimetic  agent  supposed  to  be 
responsible  for  the  adrenergic  effects  of  bitter  orange  food  supplements.  (NTP/NIEHS,  2004; 
Appendix A of the reference EFSA ESCO, 2009). 
 
Extracts of bitter orange fruits and their peel for food supplement use 
The  extracts  are  usually  standardised  for  their  (-)-synephrine  content.  Some  are  additionally 
standardised  for  related  adrenergic  phenylethylamines  (e.g.  octopamine,  hordenine).  Commercial 
extracts  are  marketed  with  a  content  of  6-10  %,  but  can  contain  up  to  95  %  (-)-synephrine 
(NTP/NIEHS 2004, Blumenthal 2005). Other biologically active constituents present in the hydro-
alcoholic extract of the (unripe) fruit of Citrus aurantium include flavonoid glycosides and low levels 
of furanocoumarins (Appendix A of the reference EFSA ESCO, 2009). 
 
Toxicity 
Animal and in vitro data 
Animal experiments, such as a 28-days-NTP (National Toxicology Program)-study in rats (Hansen, 
2012),  show  that  Citrus  aurantium  extracts  exhibit  cardiovascular  effects,  but  they  do  not  allow 
identification of NOAEL values since the dosages chosen were too high.  
No data are available on the genotoxicity of Citrus aurantium peel and its extracts.  
For (±)-synephrine (racemate) (120 μM to 21.53 mM) no mutations were observed in L5178Y mouse 
lymphoma cells (McGregor et al., 1988). 
 
 QPS approach for the safety assessment of botanicals 
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Human data 
From the human studies available, only clinical studies with a one-off intake of (-)-synephrine from 
Citrus aurantium extracts are reliable. There is a lack of suitable studies based on repeated and long-
term intake of Citrus aurantium extract with (-)-synephrine. Following a one-off dose of 54 mg of (-)-
synephrine in Citrus aurantium extract, healthy test persons without any physical exercise showed, 
compared to control, an average increase in systolic blood pressure of 7.3 mm Hg as well as slight 
acceleration of the pulse rate (Bui et al., 2006). Following administration of Citrus aurantium with 
46.9 mg of (-)-synephrine, the pulse rate increased though not the blood pressure measured (Haller et 
al., 2005). At 27 mg of (-)-synephrine in Citrus aurantium extract given as a one-off dose, there were 
no differences with regard to the length of the QT interval in the electrocardiogram (ECG), or in 
relation to systolic and diastolic blood pressure (Min et al., 2004). 
 
Use 
In traditional food the whole mature and immature fruits and their peel are used e.g. in bitter-orange 
marmalades, liqueurs and in the form of candied orange peel. Total daily intake of (-)-synephrine via 
traditional food, considering maximum concentrations of (-)-synephrine, amounts to 6.66 mg/d for 
average consumers and to 25.7 mg/d for high consumers (BfR, 2012). These values take also intake of 
(-)-synephrine via sweet oranges, lemons, mandarins and clementines and their juices into account.  
Extracts (water/alcohol) of dried immature fruits and/or peel of bitter orange have been used for food 
supplements, e.g. for herbal weight loss formulas (as an alternative to Ephedra). (-)-Synephrine is 
believed to be the active ingredient and to act as an agonist of adrenoceptors. Products are claimed to 
produce and/or maintain weight loss, improve physical fitness, and increase lean muscle mass. Such 
weight  loss  formulas  usually  contain  100-200  mg  of  bitter  orange  extract  (NTP/NIEHS,  2004; 
Blumenthal, 2005). Often these products contain in addition caffeine which is expected to enhance the 
cardiovascular effects of (-)-synephrine (Health Canada, 2011; Appendix A of the reference EFSA 
ESCO, 2009).  
In a medicinal product, the racemic mixture of (±)-synephrine having only about half of the biological 
activity of (-)-synephrine has been used in the form of the tartrate to treat cardiovascular disturbances 
(Rote  Liste,  1995;  Martindale,  2011;  Stohs  and  Preuss,  2012).  The  recommended  single  dose  is 
equivalent to 34.5 - 52 mg (-)-synephrine given three times daily, equivalent to a total dose of 103.5 - 
155 mg (-)-synephrine/d. 
 
Result of evaluation 
Following the application of the flow diagram (Figure 1), (-)-synephrine extracted from C. aurantium 
can be classified as follows:  
  thresholded substance 
  no established health-based guidance value 
  no sufficient toxicity data available to estimate a safe level of intake, but there is a history of 
use via traditional food without any reported adverse effect. It should however be underlined 
that absence of evidence for adverse effect can not be taken as an evidence for the absence of 
adverse effect(s). Considering the doses showing a pharmacological effect in humans and the 
levels of exposure resulting from the traditional use of C.aurantium preparations, there is a 
biological plausibility for an adverse health effect, although it has not been picked up by 
historical data. 
A diversity of coumarin- and furocoumarin derivatives is described as components of the essential oil 
of C. aurantium. Theoretically these compounds could occur as minor impurities in the botanical 
preparation(s) considered, although no information could be retrieved to confirm their presence in C. QPS approach for the safety assessment of botanicals 
 
EFSA Journal 2014;12(3):3593  26 
aurantium water/alcohol extracts. Still, coumarin and furocoumarin derivatives should be considered 
as substances of interest for the QPS assessment and run through the flow diagram (Figure 1). 
 
Conclusions of the assessment:  
  (-)-Synephrine is regarded as the principal substance of concern (grouped together with related 
adrenergic  phenylethylamines,  e.g.  octopamine,  hordenine).  A  diversity  of  coumarin-  and 
furocoumarin derivatives is regarded as minor impurities which theoretically may occur. Their 
intake levels should stay below possibly existing health based guidance values, or below the 
relevant TTC values in the absence of such health-based guidance values. 
  If basing the assessment on the history of use without any reported adverse effect, and in line 
with the level A of the SC guidance for the safety assessment of botanicals and botanical 
preparations (EFSA, 2009), dried hydro-alcoholic extracts of dried immature fruits and dried 
peel of the immature and mature fruits of Citrus x aurantium ssp. amara (Link) Engl. are 
suitable for QPS status, provided that the use of extracts is restricted to levels where (-)-
synephrine intakes in the form of food supplement(s) do not exceed significantly historical 
intake levels from traditional foods.  
  If one decide to ignore the history of use, considering rather the plausibility for undetected 
long  term  adverse  effects linked to  (-)-synephrine,  dried  hydro-alcoholic  extracts  of  dried 
immature fruits and dried peel of the immature and mature fruits of Citrus x aurantium ssp. 
amara (Link) Engl. would then be excluded from QPS status. 
 
Iteration process: 
Extension of the QPS status for the dried hydro-alcoholic extracts to other preparations or the entire 
immature or mature dry or fresh fruits of Citrus x aurantium ssp. amara (Link) Engl. including their 
peels 
The  extension  seems  to  be  possible  whereby  this  still  needs  verification  examining  the  existing 
database.  
 
Extension of the QPS status of entire immature or mature dry or fresh fruits Citrus x aurantium ssp. 
amara (Link) Engl. including their peels to other parts of Citrus x aurantium ssp. amara (Link) Engl. 
The question of whether extension of the QPS status to other parts of the plant used, such as leaves 
(Citri  aurantii  folium)  or  flowers  (Aurantii  amari  flos),  is  possible  has  to  be  evaluated  based  on 
relevant literature, e.g. comparing the composition data of the dried fruits and their peels with those of 
relevant other plant parts.  
 
Extension of the QPS status of entire immature or mature dry or fresh fruits of Citrus x aurantium ssp. 
amara (Link) Engl. including their peels to fruits of other subspecies of Citrus aurantium L. or of 
other species of the genus of Citrus 
Other subspecies of Citrus aurantium L., e.g. Citrus x aurantium ssp. bergamia (Risso & Poit.) Engl. 
(bergamot orange) or Citrus aurantium var. voangkely H. Perrier, are described. The genus Citrus 
comprises different species including many hybrids of which some are the source of edible, others of 
non edible fruits. According to Tanaka (1954) the term Citrus is a genus comprising 145 species (and 
12 additional new species) of which the fruits are edible or not edible. According to Swingle (1967) 
the term Citrus is more specifically defined as a subgenus comprising only 16 species which are all the 
source of edible fruits with the exception of the species of Citrus tachibana (Hager, 2006). 
Besides the fruits of Citrus aurantium L. also the fruits of other  Citrus species  may contain (-)-
synephrine.  Arbo  et  al.  (2008)  identified  (-)-synephrine  in  the  fruits  of  all  Citrus  species  they 
investigated: Citrus aurantium L., C. sinensis Osbeck, C. deliciosa Ten, C. limon Burm and C. limonia 
Osbeck. (-)-Synephrine was also found by Xing-Qian et al. (2011) in the fruits of all nine mandarin 
cultivars they analysed: C. unshiu var. praecox Tanaka cv Nichinan No. 1, C. unshiu var. praecox QPS approach for the safety assessment of botanicals 
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Tanka cv Miyagawa wase, C. unshiu Marc. cv Yamada, C. unshiu Marc. cv Owari, C. poonensis Hort. 
ex Tanaka, C. erythrosa Hort. ex Tanka, C. tardiferax Hort. ex Tanka, C. succosa Hort. ex Tanaka, C. 
suavissima Hort. ex Tanaka. 
(-)-Synephrine has also been detected by Inafuku-Teramoto et al. (2011) in the peel of the fruits of all 
the analysed Citrus species: C. depressa, C. madurensis, C. rokugatsu, C. oto, C. keraji, C. nobilis, C. 
tankan, C. tangerine. 
Other typical components of fruits belonging to the genus of Citrus in a wider sense are (i) essential 
oils and their characteristic ingredients such as terpenes, (ii) typical flavonoids such as a diversity of 
flavanones, flavones and flavonoles, (iii) coumarin derivatives such as different furocoumarins and 
hydroxycoumarins, and (iv) a diversity of limonoids (Hager, 2006).  
In  view  of  the  expected  diversity  in  composition  of  the  fruits  of  the  numerous  Citrus 
species/subspecies including all hybrids, and the biological activities of the components which may be 
present, it can only be decided on a case by case basis for each species and subspecies if it will be 
justified to extrapolate the above described QPS approach to it and if an implication of additional or 
other qualifications is necessary. A literature research would be needed regarding e.g. the composition 
of the fruits of the different individual Citrus species/subspecies to conclude which of them could be 
included in the QPS approach. This would be most promising in a first step for the edible fruits of 
Citrus species/subspecies. 
 
B.4  Foeniculum vulgare  
Species, plant parts and preparations used  
For Foeniculum vulgare two varieties can be defined including Foeniculum vulgare Mill. var. dulce 
and Foeniculum vulgare Mill. var. vulgare. From both species preparations based on the essential oil 
as well as preparations containing water based extracts might be considered. 
 
Composition  
Essential oil 
The essential oil of both species is known to contain substances of concern including trans-anethole 
and estragole (SCF, 2001a; SCF, 2001b; Council of Europe, 2006). The essential oil also contains 
estragole which is known to be genotoxic and carcinogenic. 
Water based extracts 
Given  the  limited  water  solubility  of  these  compounds  of  concern  their  concentrations  in  water 
extracts is expected to be significantly lower than in the essential oils. 
 
Toxicity 
For trans-anethole JECFA derived a temporary ADI of 0-2.0 mg/kg bw (JECFA, 1998), which can be 
used to define whether exposure of proposed uses and use levels will be safe and can be assigned QPS 
status with defined exposure restrictions. 
For estragole there are carcinogenicity data from which a BMDL10 could be derived and one could use 
the MOE approach to characterise the level of concern resulting from the exposure to this substance 
through food. However, given the recommendation of the Scientific Committee to not introduce into 
the food chain substances that are known to be genotoxic and carcinogenic (EFSA, 2005), preparations 
from Foeniculum vulgare containing estragole will have to be excluded from the QPS approach and 
therefore subject to a case-by-case assessment QPS approach for the safety assessment of botanicals 
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Use 
Fennel based teas are traditionally used in many parts of Europe including France, Germany, Austria, 
Czech  Republic  and  Poland  in  for  example  the  symptomatic  treatment  of  digestive  disorders 
alleviating  mild  spasmodic  gastro-intestinal  ailments  and  for  the  relief  of  symptoms  during 
inflammations of mucous membranes of the upper respiratory tract (EMA, 2008). Homemade fennel 
tea is often used as a remedy for gastrointestinal complaints in infants and young children (Crotteau et 
al., 2006; Perry et al., 2011). In addition various fennel-based food supplements are on the market 
containing for example the essential oil, dried extract or seeds. 
 
Result of evaluation 
Given the recommendation of the Scientific Committee to not introduce into the food chain substances 
that  are  known  to  be  genotoxic  and  carcinogenic  (EFSA,  2005),  preparations  from  Foeniculum 
vulgare containing estragole are excluded from the QPS approach and should be subject to a case-by-
case assessment. In this particular case, it should be noted that the level of estragole extracted into the 
essential oils of Foeniculum vulgare species will be higher than the levels extracted into water based 
preparations. For risk management purposes, it may be of interest to assess  preparations of these 
species on a case-by-case basis, using the carcinogenicity data for estragole from which a BMDL10 
could be derived and for which it is therefore possible to apply the MOE approach. The fact that some 
preparations e.g. essential oils of Foeniculum vulgare and Ocimum tenuiflorum species will show 
higher levels of estragole than the levels extracted into (traditional) water based preparations should 
then be taken into account. 
 
Iteration process: Given that different preparations (e.g. fine cut, whole fruits) and two varieties exist 
for Foeniculum vulgare generally used for fennel based teas, QPS status could be considered only if 
specific preparations of one or the other variety are demonstrated to be exempt of estragole.  
 
B.5  Camellia sinensis 
Species, plant parts and preparations used  
Camellia sinensis (L.) O. Kuntze 
Parts used and preparations thereof: Young leaves and leaf buds are used unfermented and dried to 
produce traditional “green tea” as the basis for traditional aqueous green tea infusions. Leaves and leaf 
buds  are  also  used  to  produce  the  so  called  “dried  aqueous  green  tea  extracts”  for  use  in  food 
supplements. (Appendix B of the reference EFSA ESCO, 2009).  
 
Composition 
Green tea 
Polyphenols: Green tea contains a diversity of polyphenolic compounds, which account for up to 30% 
of the dry weight of green tea leaves. Most of the polyphenols in green tea are flavanols, commonly 
known as catechins. The primary catechins in green tea are (-)epicatechin (EC), (-)epicatechin-3-
gallate  (ECG),  (-)epigallocatechin  (EGC),  and  (-)epigallocatechin-3-gallate  (EGCG).  Furthermore 
(+)catechin (C), (+)gallocatechin (GC), (-)gallocatechingallate (GCG), (-)catechingallate (CG), occur 
in green tea. Young leaf green tea contains lower levels of EGCG and total catechins than old leaf 
green tea (Lin et al., 2003).  QPS approach for the safety assessment of botanicals 
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Purine alkaloids: caffeine (previously referred to as theine or teine; depending upon the development 
stage of the leaves, 2.9-4.2%, content declining with age), theobromine (0.15-0.2%), theophylline 
(0.02-0.04%). 
Amino  acids:  The  total  amino  acids  content  in  green  tea  amounts  to  4%,  including  the  tea 
characteristic L-theanine as a major component (2% of green tea). 
Green tea extracts 
Green tea extracts, e.g. traditional aqueous green tea infusions or dried green tea extracts, vary in their 
compositions depending on the green tea used and the conditions of the manufacturing procedure. 
Table 1:   Contents (mean values of 3-5 determinations) of catechins in a Chinese and a Japanese 
green tea infusion (preparation: 1g tea leaves were brewed with 100 ml boiling water and decanted 
after 5 minutes). The (+)-catechin contents are below the detection limit (10 μg/ml). 
a = percentage 
referred to total catechins. (Khokar et al., 1997). 
Green tea 
infusions 
EC  
(mg/100 ml)  
ECG  
(mg/100 ml)  
EGC  
(mg/100 ml)  
EGCG  
(mg/100 ml) 
Total catechins  
(mg/100 ml)  
China   4.7 (9.1 %)
a   4.4 (8.5 %)
a   16.3 (31.7 %)
a   26.3 (51.1 %)
a   51.5  
Japan   9.4 (11.1 %)
a   5.9 (6.9 %)
a   28.7 (33.8 %)
a   40.8 (48.1 %)
a   84.9  
 
The manufacturing processes for  “dried  green  tea  extracts”  for  use  in  food  supplements  vary  in 
extraction techniques and manufacturing procedures and are not uniform. They may differ from the 
traditional green tea infusion, e.g. in the solvent being different from water, in the source (e.g. fresh 
leaves instead of green tea), in extraction conditions (e.g. degree of comminution, concentration ratios, 
temperature,  duration,  stirring)  and  in  fractionation  procedures  concentrating  active  compounds 
(Appendix B of the reference EFSA ESCO, 2009). 
 
Toxicity 
Dried green tea extracts 
Toxicokinetic  results  in  animals  and  humans  show  that  administration  of  concentrated  green  tea 
extracts  under  fasting  conditions  leads  to  a  significant  increase  of  plasma  concentrations  and 
bioavailability of EGCG compared to administration with feed or food (Appendix B of the reference 
EFSA ESCO, 2009).  
 
Animal and in vitro data 
In  three subchronic studies  in  rats  and  fasting  beagle  dogs,  NOAELs  ranging  from  40 to 50  mg 
EGCG/kg  body  weight  per  day  have  been  found  in  relation  to  organ  damage  including  hepatic 
necrosis (McCormick et al., 1999; Johnson et al., 1999; Isbrucker et al., 2006; Appendix B of the 
reference EFSA ESCO, 2009). 
A green tea preparation (consisting of 85 to 95% total catechins (by weight) and more than 55% 
EGCG) was negative in the Ames test, the rat micronucleus assay, the UDS test, and the transgenic 
mouse mutation assay, but positive in the mouse lymphoma mutation assay (FDA, 2006; Chang et al., 
2003). In an oral (gavage) carcinogenicity study, the same preparation was administered daily for 26 
weeks to p53 transgenic mice at doses up to 500 mg/kg/day. The treatment was not associated with an 
increased incidence of either neoplastic or non-neoplastic lesions in the organs and tissues examined 
(FDA, 2006).  
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Human data 
The analysis of the available human data (up to 2009) shows that in more than 30 cases, an association 
was seen between the intake of large amounts of green tea-derived products and the occurrence of, in 
some cases, severe liver damage. In many cases of these liver disorders dried green tea extracts with 
high EGCG contents were taken in capsule form over several months as a medicinal product or food 
supplement to support weight-loss. Concerning the treatment with an oral phytotherapeutical drug the 
daily intake of 2 capsules to 5 capsules (187.5 – 468.75 mg EGCG/ day), mostly 4 capsules (375 mg 
EGCG/ day) was associated with liver damage. A causal relationship has to be regarded as probable in 
7 cases and as possible in 27 cases (Sarma et al., 2008; Appendix B of EFSA ESCO, 2009). 
 
Use 
Worldwide long-time consumption of traditional green tea infusions has to be taken into consideration. 
Beverages prepared from dried aqueous green tea extracts (ready to drink or prepared from instant 
preparations) show a similar composition, i.e. do not exceed the concentrations of polyphenols in 
traditional  infusions,  and  are  therefore  under  qualitative  and  quantitative  aspects  equivalent  to 
traditional green tea infusions.  
Exposure data exist for traditional uses as a stimulant drink in the form of green tea infusions (see 
Table 4 of Appendix B of the reference EFSA ESCO, 2009). 
Food supplements or related products on the basis of dried green tea extracts, e.g. for the purpose of 
supporting weight reduction, have been described with a daily dose representing the equivalent of 
minimum 150 mg caffeine, 115-270 mg EGCG, and 375 mg catechins) (Appendix B of the reference 
EFSA ESCO, 2009). 
A medicinal weight-loss product containing a high-dosed hydroalcoholic extract of green tea was 
marketed  only  until  April  2003,  when  the  French  and  Spanish  authorities  suspended  the  market 
authorisation because of hepatotoxic side-effects (AFSSAPS, 2003; Sarma et al., 2008). 
 
Result of evaluation 
(-)Epigallocatechin-3-gallate (EGCG) is the major catechin in green tea extracts and is associated with 
liver toxicity seen in animals and humans after exposure with dried green tea extracts under certain 
conditions. 
Classification of EGCG found in dried green tea extracts for food supplement use according to the 
decision tree:  
  thresholded substance 
  established health-based guidance value 
In the evaluation of dried green tea extracts for food supplement use, reference to a NOAEL ranging 
from  40  to  50  mg  EGCG/kg  body  weight  per  day  according  to  the  results  of  three  out  of  five 
subchronic studies is made (Appendix B of the reference EFSA ESCO, 2009). By applying a safety 
factor of 100, a maximum intake of 0.5 mg EGCG/kg body weight per day with dried aqueous green 
tea  extracts  used  in  food  supplements  can  be  accepted  under  the  conditions  that  the  extracts  are 
manufactured under the same extraction conditions as applied in the traditional preparation of green 
tea infusions and that the extracts are not used for products for weight reduction purposes (Appendix B 
of the reference EFSA ESCO, 2009).  QPS approach for the safety assessment of botanicals 
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Conclusion of the assessment: apart from the worldwide long-time consumption of traditional green 
tea infusions
4, which is regarded as safe
5, QPS status could be granted to dried extracts of unfermented 
and dried leaves and leaf buds of Camellia sinensis (L.) O. Kuntze with the following qualifications: 
  a maximum intake of 0.5 mg EGCG/kg body weight per day with dried aqueous green tea 
extracts used in food supplements. 
  the extracts are manufactured under the same extraction conditions as applied in the traditional 
preparation of green tea infusions. 
  The attention of the risk manager should be brought to the increased bioavailability of EGCG 
when taken in the fasting state. 
  In addition the possible presence of caffeine in the dried extracts has to be taken into 
consideration.  
 
Iteration process: 
Extension of the QPS status of dried aqueous extracts of unfermented dried leaves and leaf buds of 
Camellia sinensis (L.) O. Kuntze to the entire unfermented dried or fresh leaves and leaf buds of 
Camellia sinensis (L.) O. Kuntze 
Considering the available database this seems not to be possible. 
 
Extension of the QPS status of dried aqueous extracts of unfermented dried leaves and leaf buds of 
Camellia sinensis (L.) O. Kuntze to extracts of a) fermented/semifermented dried leaves and leaf buds 
or b) of other parts of Camellia sinensis (L.) O. Kuntze  
Depending on the manufacturing process mainly three different traditional tea products are prepared 
from the leaves and leaf buds of C. sinensis: Green tea, black tea and oolong tea. While “green tea” is 
produced without fermentation and thus preventing oxidation of the polyphenolic components, “black 
tea” manufacture is carried out by fermentation ensuring a high degree of enzymatically catalysed 
aerobic oxidation of the polyphenols followed by a series of chemical condensations. In “oolong tea”, 
a  semifermented  tea,  polyphenols  are  partially  oxidized.  Thus  unfermented,  semifermented  and 
fermented dried leaves and leaf buds of C. sinensis differ in their chemical composition as do their 
extracts. 
The question of whether extension of the QPS status to extracts of fermented/semifermented dried 
leaves and leaf buds or of other parts of the plant, such as blossoms or roots, is possible, has to be 
evaluated based on relevant literature and comparing the composition data of the botanicals and their 
extracts.  
 
Extension of the QPS status of dried aqueous extracts of unfermented and dried leaves and leaf buds 
of Camellia sinensis (L.) O. Kuntze to extracts of leaves and leaf buds of other species of the genus 
Camellia 
The genus Camellia comprises about 80 different species (Hager, 2006) of which only the species 
Camellia  sasanqua  Thunb.  containing  sasanqua  triterpenoid  saponins,  is  listed  besides  Camellia 
sinensis  (L.)  O.  Kuntze  in  the  EFSA  Compendium  of  botanicals  reported  to  contain  naturally 
occurring substances of possible concern for human health when used in food and food supplements 
(EFSA Scientific Committee, 2012). In view of the expected diversity in composition of the leaves 
and leaf buds of the numerous Camellia species and the biological activities of the components which 
                                                       
4  Beverages  prepared  from  dried  aqueous  green  tea  extracts  (ready  to  drink  or  prepared  from  instant 
preparations), that have a similar composition and do not exceed the concentrations of polyphenols in traditional 
infusions, are regarded to be equivalent to traditional green tea infusions 
5 
2 This conclusion holds provided that pregnant and nursing mothers as well as children and other caffeine 
sensitive persons consume the beverage in moderation or abstain from it (general recommendation for caffeine 
containing beverages postulated to be common knowledge). QPS approach for the safety assessment of botanicals 
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may be present, it can only be decided on a case by case basis for each species if it will be justified to 
extrapolate  the  above  described  QPS  approach  to  it  and  if  an  implication  of  additional  or  other 
qualifications is necessary. A literature research would be needed regarding e.g. the composition of the 
leaves and leaf buds of the different individual Camellia species to conclude which of them could be 
included in the QPS approach.  
 
B.6  Ocimum tenuiflorum  
Species, plant parts and preparations used  
Ocimum tenuiflorum L. (Synonym Ocimum sanctum L.) 
Parts used: Leaf: spice (Thai cuisine) but also used in traditional systems like the Indian Ayurveda 
(Pattanayak et al. 2010). Essential oil from leaf (EFSA, 2012).  
 
Composition  
Leaf: 2% Essential oil (EFSA 2012), 2% ursolic acid, a pentacyclic triterpenoid (3β)-3-hydroxy-urs-
12-en-28-oic  acid)  (Silva  et  al.  2008).The  essential  oil  contains  eugenol  (up  to  62%)  and 
methyleugenol (up to 86%), 7-25% methylchavicol (estragole) and 7-23% 1,8-cineole (eucalyptole) 
(EFSA, 2012, Zheljazkov et al. 2008). The leaf is also reported to contain alkaloids and saponins 
(EFSA, 2012). 
 
Toxicity 
Reproductive toxicity 
Leaves are used as a human abortifacient in India (Prakash & Gupta 2005, Ahmed et al. 2002b). There 
is no information on the doses used. 
A preliminary study using fresh leaves 1 g/kg body weight/day resulted in vaginal bleeding. Feeding 
with fresh leaves of O. tenuiflorum (1 g/kg bw) twice a week for one month in adult rabbits caused 
significant  changes  in  the  histology  of  the  testis,  epididymis,  uterus  and  ovary.  Pregnancy  and 
subsequent delivery occurred only in those rabbits which were allowed to mate one month after the 
stoppage of the leaves feeding period as compared to those rabbits allowed to mate directly after the 
stoppage of the feeding period (Reghunandan et al. 1997). This indicates that the effect under certain 
condition might be reversible (EFSA ESCO, 2009).  
Other studies in male rats, mice and rabbits have shown various effects on male fertility, decreased 
sperm count, weight changes and/or histological effects on testes or accessory sex organs after peroral 
intake of the dried leaf and stem, with benzene extracts and water extracts (Khanna et al. 1986, Kantak 
and Gogate 1992, Ahmed et al. 2002a,b, Ahmed et al. 2009, Sethi et al. 2010, Pragya et al. 2012). The 
dried leaf and stem caused effect on oestrus cycle and fertility in female rats (Khanna et al. 1986).  
Genotoxicity and carcinogenic effects 
The  genotoxicity  and  carcinogenicity  of  methyleugenol  have  been  well  documented  (SCF  2001b, 
Rietjens et al. 2008). 
 
Use: 
No exposure data exist for use as a spice/culinary herb in Thai cuisine.  QPS approach for the safety assessment of botanicals 
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Therapeutic/medicinal use: Fresh leaves 2 g/kg body weight/day for 30 days (Sethi et al. 2008). Dried 
leaves: 300-2000 mg/day as a single dose and 600-2000 mg in multiple doses. Infusions 2 g dried 
leave per cup of water or 2.5 g dried leaf/day. Leaf juice: 10-20 ml of fresh leaf juice (EFSA, 2012). 
No information on recommended dose levels of other plant parts.  
 
Result of evaluation 
The plant species and the plant parts are well-defined (first box in flow diagram).  
The chemical analytical data do not provide adequate compositional data. The chemical(s) of concern 
for  the  reproductive  effects  have  not  been  pinpointed.  The  information  on 
compositional/toxicological/use data is insufficient. Moreover, O. tenuiflorum‟s leaves are reported to 
contain genotoxic and carcinogenic substances. O. tenuiflorum L. (leaf) is therefore excluded from the 
QPS approach. 
 
Iteration process: 
Not applicable due to inadequate compositional/toxicological/use data. QPS approach for the safety assessment of botanicals 
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GLOSSARY  
History of safe use  The  safety  of  the  food  in  question  is  confirmed  with 
compositional data and from experience of use and continued 
use for at least 25 years in the customary diet of a large part 
of the population of a country 
Council of the European Union (2009). Proposal for a Regulation 
of the European Parliament and of the Council on novel foods and 
amending Regulation (EC) No 1331/2008 (common position) 
 
Margin of exposure  Ratio of the no-observed-adverse-effect level or benchmark 
dose  lower  confidence  limit  for  the  critical  effect  to  the 
theoretical,  predicted  or  estimated  exposure  dose  or 
concentration. 
FAO/WHO International Programme on Chemical Safety, 2009. 
Environmental Health Criteria 240 – Principles and Methods for 
the  Risk  Assessment  of  Chemicals  in  Food.  ISBN:  978-92-4-
157240-8 
Margin of safety  The  margin  between  the  health-based  guidance  value 
(reference dose) and the actual or estimated exposure dose or 
concentration.  
FAO/WHO International Programme on Chemical Safety, 2009. 
Environmental Health Criteria 240 – Principles and Methods for 
the  Risk  Assessment  of  Chemicals  in  Food.  ISBN:  978-92-4-
157240-8 
 
ABBREVIATIONS 
ANS  Panel on Food Additives and Nutrient Sources Added to Food  MOS  Margin of Safety 
BMDL10  Lower confidence bound of the benchmark dose for a 10% response  NDA  Panel on Dietetic Products, Nutrition and Allergies 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids   QPS  Qualified Presumption of Safety 
FEEDAP  Panel on Additives and Products or Substances used in Animal Feed   (Q)SAR  (Quantitative) Structure Activity Relationship 
MOA  Mode of Action  SC  Scientific Committee 
MOE  Margin of Exposure  TTC  Threshold of Toxicological Concern 
 